U.S. markets closed

Omeros Corporation (OMER)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.0900-0.0600 (-1.90%)
At close: 04:00PM EST
3.0700 -0.02 (-0.65%)
After hours: 07:24PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected


Previous Close3.1500
Bid3.0500 x 800
Ask3.3000 x 800
Day's Range2.9900 - 3.1800
52 Week Range1.7400 - 7.7500
Avg. Volume563,049
Market Cap193.836M
Beta (5Y Monthly)1.11
PE Ratio (TTM)0.98
EPS (TTM)3.1390
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for OMER

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Omeros Corporation
    Analyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
    Fair Value
    Economic Moat
View more
  • Business Wire

    Omeros Corporation Reports Third Quarter 2022 Financial Results

    SEATTLE, November 09, 2022--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation and immunologic diseases, including complement-mediated diseases and cancers, today announced recent highlights and developments as well as financial results for the third quarter ended September 30, 2022, which include:

  • Business Wire

    Omeros Corporation Receives Decision from FDA on Formal Dispute Resolution Request for Narsoplimab

    SEATTLE, November 08, 2022--Omeros Corporation (Nasdaq: OMER) today announced that the Office of New Drugs (OND) of the U.S. Food and Drug Administration (FDA) has reached a decision on the company’s formal dispute resolution request appealing the issuance by FDA’s Office of Cardiology, Hematology, Endocrinology and Nephrology (OCHEN) and the Division of Nonmalignant Hematology (the review division) of a complete response letter (CRL) concerning the biologics license application (BLA) for narsop

  • Business Wire

    Omeros Corporation to Announce Third Quarter Financial Results on November 9, 2022

    SEATTLE, November 04, 2022--Omeros Corporation (NASDAQ: OMER), today announced that the company will issue its third quarter financial results for the period ended September 30, 2022, on Wednesday, November 9, 2022, after the market closes. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss the financial results as well as recent developments and highlights.